Bio-Rad Laboratories (BIO) Gains from Investment Securities (2010 - 2026)

Bio-Rad Laboratories (BIO) has 17 years of Gains from Investment Securities data on file, last reported at $33.3 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $33.3 million, up 321.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $87.0 million (up 1060.0% YoY), and the FY2025 annual result was $61.6 million, up 1711.76% from the prior year.
• Gains from Investment Securities slipped to $33.3 million in Q1 2026 per BIO's latest filing, from $59.0 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $81.5 million in Q3 2023 and troughed at -$72.3 million in Q4 2024.
• A 5-year average of $10.7 million and a median of $13.4 million in 2022 frame the typical range for Gains from Investment Securities.
• On a YoY basis, Gains from Investment Securities climbed as much as 49651.85% in 2022 and fell as far as 367.47% in 2022.
• A 5-year view of Gains from Investment Securities shows it stood at $54.2 million in 2022, then plunged by 223.43% to -$66.9 million in 2023, then slipped by 8.03% to -$72.3 million in 2024, then soared by 181.6% to $59.0 million in 2025, then slumped by 43.56% to $33.3 million in 2026.
• Business Quant data shows BIO's Gains from Investment Securities at $33.3 million in Q1 2026, $59.0 million in Q4 2025, and $2.5 million in Q3 2025.